产品介绍
| 产品名称 Anti-FOLR2抗体[EPR25731-70] (BSA and Azide free) 参阅全部 FOLR2 一抗 描述 兔单克隆抗体[EPR25731-70] to FOLR2 - BSA and Azide free 宿主 Rabbit 经测试应用 适用于: ICC/IF, IHC-Pmore details 不适用于: Flow Cyt,IP or WB 种属反应性 与反应: Human 不与反应: Mouse, Rat 免疫原 Recombinant fragment. This information is proprietary to Abcam and/or its suppliers. 阳性对照 WB: His-tagged human FOLR2 recombinant protein. IHC-P: Human: liver, stomach and placenta tissue. ICC/IF: THP-1 (human monocytic leukemia monocyte). 常规说明 ab302533 is a carrier-free version of ab302532. We do not recommend this RabMAb for WB with endogenous lysates. ab302532 does not react in: IHC-P with mouse and rat; ICC with mouse. This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com. Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc. This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free production For more information see here. Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents. |